# Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rectal Cancer

> **NCT02864849** · PHASE2 · COMPLETED · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 81 (actual)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **RADIATION:** Intensity modulated radiotherapy
- **PROCEDURE:** Total mesorectal excision

## Key facts

- **NCT ID:** NCT02864849
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2019-06
- **Final completion:** 2019-06
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2021-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02864849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02864849, "Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02864849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*